C19orf18 Inhibitors
C19orf18 inhibitors encompass a range of chemical compounds that, while not directly targeting C19orf18, are capable of impinging upon the cellular pathways that C19orf18 may be a part of. For instance, kinase inhibitors such as Staurosporine can broadly inhibit protein kinases which may be necessary for the phosphorylation and subsequent activation of C19orf18. Similarly, PI3K inhibitors like LY294002 and Wortmannin are capable of impeding the PI3K/Akt signaling axis, a pathway that could be vital for the regulation and function of C19orf18. If C19orf18 is involved in signal transduction that relies on phosphorylation by PI3K, these inhibitors could lead to a decrease in its functional activity.
Other compounds such as Rapamycin and U0126 work by targeting key components of growth and survival pathways, namely mTOR and MEK. Rapamycin's inhibition of mTORC1 can disrupt protein synthesis and other cellular processes that may be crucial for C19orf18 functionality. U0126, by inhibiting MEK1/2, can attenuate the ERK signaling pathway, which, if relevant to C19orf18's role, can result in decreased activity of the proteinGiven the lack of direct inhibitors and specific information about C19orf18's involvement in particular signaling pathways, the following table is constructed on the premise that C19orf18 could logically be involved in common cellular pathways based on the functions of similarly situated proteins
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a broad spectrum of protein kinases, potentially affecting pathways that C19orf18 may be involved in, leading to its functional inhibition by preventing necessary phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/Akt signaling cascade. If C19orf18 functions downstream of this pathway, inhibition of PI3K can lead to reduced activity of C19orf18 by limiting activation signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, similar to LY294002, that can suppress the PI3K/Akt pathway, possibly leading to decreased activity of C19orf18 if it relies on this pathway for its activation or stability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTORC1, potentially affecting protein synthesis pathways that could be essential for the function or expression of C19orf18, thus leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that can reduce ERK pathway signaling. If C19orf18 is an effector within this pathway, U0126-induced inhibition could lead to reduced C19orf18 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that may decrease the activation of downstream effectors, potentially including C19orf18 if it is involved in stress response pathways mediated by p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that may prevent the activation of transcription factors and other proteins that could interact with C19orf18 or regulate its activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
A Gsα subunit inhibitor that can reduce cAMP levels, potentially affecting pathways that C19orf18 could be involved in, leading to its functional inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor that affects cytoskeletal dynamics. If C19orf18 is associated with signaling pathways involving the cytoskeleton, Y-27632 could lead to its inhibition. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
V-ATPase inhibitor affecting endosomal acidification and autophagy. If C19orf18 is involved in these processes, Bafilomycin A1 can result in decreased activity of C19orf18. | ||||||